These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 7833483

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
    Saris A, Pavenski K.
    Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Leukocyte depletion of blood products and anti-HLA immunization].
    Valla A.
    Rev Fr Transfus Hemobiol; 1993 Jun; 36(3):281-91. PubMed ID: 8347251
    [Abstract] [Full Text] [Related]

  • 25. Clinical aspects of platelet transfusions.
    Murphy MF, Waters AH.
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):389-96. PubMed ID: 1893071
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness.
    Mishima Y, Tsuno NH, Matsuhashi M, Yoshizato T, Sato T, Ikeda T, Watanabe-Okochi N, Nagura Y, Sone S, Kurokawa M, Okazaki H.
    Transfus Apher Sci; 2015 Feb; 52(1):112-21. PubMed ID: 25467707
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions.
    Pappalardo PA, Secord AR, Quitevis P, Haimowitz MD, Goldfinger D.
    Transfusion; 2001 Aug; 41(8):984-7. PubMed ID: 11493728
    [Abstract] [Full Text] [Related]

  • 31. [Antibody formation after filtered blood cell replacement in hematologic-oncologic patients].
    Barz D, Staack D, Lehmann R, Stange K, Schnurstein K.
    Beitr Infusionsther Transfusionsmed; 1996 Aug; 33():30-4. PubMed ID: 8974705
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R.
    Vox Sang; 1998 Aug; 74 Suppl 2():359-63. PubMed ID: 9704468
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Alloimmune refractoriness to platelet transfusions.
    Sandler SG.
    Curr Opin Hematol; 1997 Nov; 4(6):470-3. PubMed ID: 9359008
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Absence of anti-D alloimmunization in hematologic patients after D-incompatible platelet transfusions.
    Cid J, Ortin X, Elies E, Castellà D, Panadés M, Martín-Vega C.
    Transfusion; 2002 Feb; 42(2):173-6. PubMed ID: 11896331
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Frequency and causes of refractoriness in multiply transfused patients.
    Legler TJ, Fischer I, Dittmann J, Simson G, Lynen R, Humpe A, Riggert J, Schleyer E, Kern W, Hiddemann W, Köhler M.
    Ann Hematol; 1997 Apr; 74(4):185-9. PubMed ID: 9174547
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.